Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib versus lenvatinib after immune checkpoint inhibitor for advanced hepatocellular carcinoma
jRCT1031210167Phase 3Active, not recruiting
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in hepatocellular carcinoma (HCC) comparing Sorafenib arm with Lenvatinib arm (2 arms). Primary endpoint: Overall survival. Started Sep 2021; status: active, not recruiting.
02
Drugs
sorafeniblenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT1031210167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031210167.